Related Experiment Video
Updated: Jan 30, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
NONVALVULAR ATRIAL FIBRILLATION AND DIABETIC NEPHROPATHY: EPIDEMIOLOGY, PROGNOSIS, AND CHOICE OF ANTICOAGULANT
Natalya A Koziolova1, E A Polyanskaya, M V Surovtseva
1ФГБОУ ВО «Пермский государственный медицинский университет им. акад. Е. А. Вагнера» Минздрава России. nakoziolova@mail.ru.
Insights
Patients with type 2 diabetes and chronic kidney disease face higher risks of bleeding, clots, and death. Novel oral anticoagulants
Area of Science:
- Cardiology
- Nephrology
- Endocrinology
Background:
- Atrial fibrillation (AF) is common in patients with type 2 diabetes (T2D), diabetic nephropathy, and chronic kidney disease (CKD).
- Comorbidities like T2D and CKD significantly impact the risk of adverse events in AF patients.
Purpose of the Study:
- To review the prevalence of AF in patients with T2D, diabetic nephropathy, and CKD.
- To evaluate the efficacy and safety of anticoagulants in this complex patient population.
Main Methods:
- Literature review of studies on AF, T2D, diabetic nephropathy, CKD, and anticoagulant use.
- Analysis of data regarding bleeding, thromboembolic complications, and mortality risks.
Main Results:
- Patients with nonvalvular AF, T2D, and CKD have increased risks of bleeding, thromboembolism, and all-cause death.
- Warfarin may be less effective and increase bleeding risk in CKD due to poor INR control and arterial calcification.
- Novel oral anticoagulants (NOACs) efficacy and safety are influenced by comorbidities, necessitating dose adjustments or alternative selections based on renal function.
Conclusions:
- Diabetic nephropathy requires careful monitoring of renal function to guide anticoagulant choice and dosing.
- Limited data from randomized controlled trials hinders definitive anticoagulant selection for patients with end-stage CKD, including those on hemodialysis or post-transplantation.
Abstract:
In this review we present data on prevalence of atrial fibrillation (AF) among patients with type 2 diabetes (T2D), diabetic nephropathy and chronic kidney disease (CKD). Patients with nonvalvular AF and T2D combined with CKD have elevated risk of both bleeding and thromboembolic complications, as well as of all cause death. Efficacy and safety of novel oral anticoagulants (NOAC) depend on comorbidities and can be determined by the presence of T2D and/or diabetic nephropathy. Use of warfarin in CKD in some cases provides no preventive effect relative to risk of stroke and is characterized by increased risk of bleeding because of poor INR control, and possibly development of calcification of arteries. Presence of diabetic nephropathy requires monitoring of renal filtration function for correction of doses or selection of another anticoagulant. Lack of data from randomized controlled trials hampers choice of anticoagulant therapy in patients with terminal CKD on hemodialysis or after renal transplantation.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Introduction to Epidemiology
Causality in Epidemiology
Mate Choice

